IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o.

Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.

CytoDyn (OTCMKTS:CYDY - Get Free Report) and Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends. Risk and Volatility CytoDyn has a beta of

Contrary to what investors have seen this earnings season, earnings growth is traditionally one of the key indicators of stock price growth. For calendar year 2026, FactSet forecasts earnings growth of companies in the S&P 500 to come in at 15%.

IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $2.30 and traded as high as $5.00. Ironwood Pharmaceuticals shares last traded at $4.86, with a volume of 1,594,030 shares traded. Analyst Upgrades and Downgrades A

Stocks like IPGP, DG, IRWD and SAIC are seeing price strength and have a high chance of carrying the momentum forward.

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.